Trial site
The University of Osaka Hospital
Suita-shi, Osaka 565-0871, JapanNot linked to an institution yet
The trials here
What the 15 trials at this site are about, from their registry records.
- Phase
- Phase 313 trials
- Phase 11 trial
- Phase 41 trial
- Status
- Recruiting11 trials
- Active, not recruiting4 trials
- Lead sponsor
- Boehringer Ingelheim4 trials
- Amgen3 trials
- Astellas Pharma Inc1 trial
- Biogen1 trial
- Daiichi Sankyo1 trial
- and 5 more
Running trials
Recruiting
Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1
NCT07486934· Phase 3· Dyne Therapeutics· Source
Contact: Masanori Takahashi
Recruiting
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
NCT07284849· Phase 3· Incyte Corporation· Source
Recruiting
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
NCT07213674· Phase 3· Amgen· Source
Active, not recruiting
A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular Degeneration
NCT06970665· Phase 4· Astellas Pharma Inc· Source
Recruiting
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)
NCT06962800· Phase 3· Biogen· Source
Contact: US Biogen Clinical Trial Center
Recruiting
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
NCT06935370· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
NCT06644781· Phase 3· Daiichi Sankyo· Source
Recruiting
ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants
NCT06787144· Phase 1· Enliven Therapeutics· Source
Contact: Yuzo Tomonaga
Active, not recruiting
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
NCT06691984· Phase 3· Amgen· Source
Recruiting
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
NCT06632457· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
NCT06632444· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
NCT06252649· Phase 3· Amgen· Source
Active, not recruiting
A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma (G-HOPE-001)
NCT06238843· Phase 3· Innovent Biologics (Suzhou) Co. Ltd.· Source
Recruiting
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
NCT06424288· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Active, not recruiting
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
NCT04468659· Phase 3· Eisai Inc.· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error